Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

ICRF-187 is the D-enantiomer of the racemic antitumor agent ICRF-159 and was selected for clinical trials on the basis of aqueous solubility suitable for iv administration. Eighteen patients with refractory advanced solid tumors received ICRF-187 by a 48-hour continuous iv infusion in 5% Dextrose in Water, USP. The total dose ranged from 200 to 1000 mg/m2/48 hours. Courses were repeated at 22--28-day intervals. The major toxic effect was reversible granulocytopenia, with the nadir on Day 12 and the recovery by Day 22. At a dose of 1000 mg/m2/48 hours, the median nadir total wbc count was 1700/mm3 (range, 1300--2600), and the median nadir granulocyte count was 597/mm3 (range, 270--1300). Platelet count nadirs of less than 100,000/mm3 occurred in only three of 16 courses at this level. Granulocyte toxicity was not cumulative and was less severe in repeated courses (median nadir, 1000/mm3 in courses two and three). Mild nausea, malaise, and three instances of alopecia were the only nonhematologic toxic effects encountered. Compared to other schedules, a continuous 48-hour infusion of ICRF-187 seems to have greater toxic effects for a given total dose, and this may predict greater biologic effect. A starting dose of 1000 mg/m2 by a 48-hour continuous infusion is recommended for phase II trials.
 ...
PMID:Phase I trial of ICRF-187 by 48-hour continuous infusion. 678 40

33 patients, who underwent maxillo-facial surgery, were fed with the instant formula diet Nutricomp F via a nasogastric tube for a mean time of 10 days. According to intolerance tube feeding had to be interrupted in 3 patients. Other side effects of nutrition with Nutricomp F were diarrhea (2,9%), nausea (1,2%), vomiting (1,2%) and eructation (1,2%). The mean frequency of defecation was 0,64/day. Glucose content of the blood, water balance, body weight, serum electrolytes, liver enzymes, acid-base-balance and the protein content of the serum did not change significantly. The postoperative increase of urea content in the serum is believed to be independent from formula diet.
 ...
PMID:[Postoperative nutrition of maxillary surgery patients with the instant formula diet]. 681 64

Acute pancreatitis in a patient on oral contraceptive therapy is reported, and the relationship of estrogen administration to hyperlipemia and pancreatitis is discussed. A 23-year-old white woman was admitted to a hospital with epigastric pain, nausea, and vomiting. Three previous episodes of abdominal pain had been diagnosed as acute pancreatitis. On the present and previous admissions, she had just completed a cycle on her combination norethindrone 1 mg, mestranol 8 micrograms contraceptive. Laboratory results showed mild leukocytosis and elevated concentrations of blood glucose, alkaline phosphatase, serum amylase, and urine amylase. Serum cholesterol and triglycerides were elevated, and lipoprotein electrophoresis showed a type IV pattern. Abdominal sonogram revealed a normal pancreas, and all other test results were normal. The patient was treated with i.v. fluid replacement, dimenhydrinate, and meperidine hydrochloride. Within 72 hours she was asymptomatic, and serum amylase, triglyceride, and cholesterol concentrations had decreased. She was discharged with a diagnosis of acute pancreatitis secondary to oral-contraceptive-induced hyperlipidemia. Oral contraceptive therapy was not resumed. Predisposing factors, symptoms, and laboratory findings associated with estrogen-induced acute pancreatitis are presented, and the mechanisms through which serum lipid elevations and subsequent pancreatitis occur are discussed. Monitoring serum lipid concentrations before and during estrogen therapy is recommended. Research suggests that patients who are over 40 years old or have family histories of hyperlipemia are at particular risk, and that estrogen therapy should be discontinued if pancreatitis occurs.
 ...
PMID:Estrogen-induced pancreatitis. 688 34

A low-lactose milk was evaluated for taste acceptance and clinical symptomatology by means of a double-blind control study in two groups of individuals. One group consisted of nine milk intolerant individuals, while the other consisted of five milk tolerant individuals. Each week for 9 wk the participants were given a coded sample of skim milk, lactose hydrolyzed milk, skim milk plus glucose, or sweet acidophilus milk. Each participant was asked to consume four liters of milk during a week and keep a daily log of symptoms (pain, bloating, nausea, flatus, emesis, bowel frequency) along with taste acceptability. After assigning a numerical value to the intensity of symptomatology a X2 analysis was performed on the data. In the milk intolerant population lactose hydrolyzed milk produced significantly milder (p < 0.05) pain and gas symptoms than the nonhydrolyzed milks. Bowel frequency was not altered between the types of milk in both groups. The lactose hydrolyzed milk did not reduce the symptoms of lactose intolerance in the milk intolerance population to the response of the control group. Although both study populations found decreased taste acceptability to the lactose hydrolyzed milk, a taste panel assessment did not show any significant differences in the milks.
 ...
PMID:Clinical studies with low-lactose milk. 689 87

Advice is provided for nurses and midwives who are asked about the safety and efficacy of the newer oral contraceptives (OCs). The trend toward ever smaller amounts of estrogen in new formulations effectively halted when the quantities of estrogen became insufficient to suppress the hypothalamic-pituitary axis or drug interactions with barbiturates or oral antibiotics resulted in insufficient estrogen, both conditions resulting in higher pregnancy rates. The newest generation of OCs follows 2 basic approaches, phasic OCs and improved progestogens. The triphasic pills Logynon and Trinordiol come in memo-packets with pills of 3 different progestogen-estrogen balances to be taken for 21 days. They contain 30 g less total monthly hormone than any other combined pill, give excellent cycle control and high reliability, and produce minimal metabolic changes. Bi-Novum, a biphasic pill with 35 mcg estrogen, gives cycle stability and minimal nausea, weight gain, and breast tenderness, comparable to results with 50 mcg estrogen. The progestogen used in Bi-Novum produces minimal changes in lipid metabolism and glucose tolerance safety factors. Another new formulation, Marvelon, is a conventional combined type pill containing a new progestogen, desogestrel, which favorably affects high density lipoprotein-cholesterol ratios, remobilizes cholesterol deposits from arterial walls, and reduces the risk of cardiovascular disesase. The progestogen-only formulation Femulen, with a daily dose of 5 mg of ethynodiol diacetate, has high efficacy and a relatively low dropout rate due to irregular bleeding and other causes.
 ...
PMID:When patients ask about the latest and safest oral contraceptive. 692 41

This study compares the frequency of dialysis disequilibrium symptoms (DDS), in 17 stable non-diabetic chronic hemodialysis patients, during a period using low glucose (200 mg/100 ml) dialyzate to a similar period using a glucose free dialyzate. There was a significant decrease in the total number of symptoms as well as the frequency of headache and post-dialysis fatigue during the low glucose period as compared to the glucose free period. The decrease in nausea or vomiting, and cramps was not significant while frequency of hypotension was unchanged. Evaluation of serum sodium, potassium, BUN, glucose and osmolarity did not reveal significant differences during the two periods. Dialysis with a low glucose bath produces less DDS than glucose free dialyzate.
 ...
PMID:Improvement in disequilibrium symptoms during dialysis with low glucose dialyzate. 714 23

The effect of guar (15.6 g/day), a dietary fibre, and simultaneous administration of bezafibrate (600 mg/day) during dietetic treatment on the plasma lipoproteins and apolipoproteins was investigated in 12 patients with familial hypercholesterolemia (corresponding to the HLP type IIa pattern). Either bezafibrate alone or bezafibrate in combination with guar was administered in a cross-over study for 3 months. Guar led to an additional lowering of the total cholesterol in the plasma by 7% (P less than or equal to 0.05) associated with a fall of the low density lipoprotein cholesterol (LDL-cholesterol (LDL-cholesterol) by 13% (P less than or equal to 0.01) without any changes in the very low density lipoprotein (VLDL) and high density lipoprotein (HDL) cholesterols. In parallel with the decrease in LDL-cholesterol, the apoprotein B also was diminished by 20% (P less than or equal to 0.05). The plasma triglyceride level and the triglyceride distribution within the individual lipoprotein fractions were not altered in any consistent manner by the addition of guar. Neither the fasting plasma glucose level nor the body weight were affected. The side-effects due to guar treatment consisted of slight nausea, meteorism and constipation, but this did not in any of the cases lead to early termination of the study. These results demonstrate that guar exerts its cholesterol-lowering effect in addition to that of bezafibrate.
 ...
PMID:Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar. 715

Mild tail pinch (TP) in rats resulted in 72% of animals displaying ingestive behavior with 20% demonstrating gnawing behavior without food ingestion and 8% demonstrating licking behavior only. The animals ate steadily over 5 min with a maximum rate occurring at 1 min (0.5 +/- 0.2 g). There was a circadian rhythm of TP-induced behavior with the peak food ingestion occurring at 24 h. A mild increase in blood glucose occurred 120 s after commencement of TP (115 +/- 4 mg/dl). Common satiety signals such as stomach distension and glucose decreased food ingestion. Parenteral administration of glucagon, cholecystokinin-octapeptide, bombesin, and thyrotropin-releasing hormone resulted in suppression of TP-induced food ingestion. Chronic TP (12 5-min TP periods/day) resulted in a fall in spontaneous food intake with the total intake remaining similar to food intake prior to the chronic TP period. We suggest that TP serves as an excellent model for eating behavior because 1) it correlates well with starvation-induced eating; 2) it precludes the necessary deprivation of food and water to adrenalectomized animals; and 3) animals subjected to TP continue chewing in the face of decreased food intake allowing one to exclude the possibility that the effects of an anorectic are secondary to nausea.
 ...
PMID:Stress-induced eating in rats. 719 55

A discussion of the side effects of hormonal oral contraceptive (OC) use is presented. Studies show that the estrogen component of OCs works to suppress the release of GRH (gonadotropin-releasing hormone), reducing the serum FSH level. The gestagen component desensitizes the frontal lobe of the pituitary gland to the effect of GRH and suppresses the preovulatory LH peak. OCs can cause subjective side effects such as nausea, headache, depression, which can also be observed during placebo use. Breakthrough bleeding, spotting, silent menstruation, and post-pill amenorrhea are menstrual irregularities which can be linked to OC use; 98% of those who discontinue OC use show normal biphasic menstrual cycles 3 cycles after discontinuation. A constant increase in serum triglyceride levels, small increases in cholesterol and phospholipid levels are observed among OC users. Minor cases of hyperinsulinism are observed among OC users with no history of diabetes; glucose tolerance tests should be regularly administered to OC users who have a risk of diabetes or a history of pregnancy diabetes. Serum levels of proteins are affected by OC use, probably due to the effects of OC use on liver function. Studies have shown an increased risk of thromboembolism and circulatory disorders among OC users, especially those who are over 30 years of age or who smoke. OC use has been linked to development of benign tumors of the liver and the cervix. Gestagens appear to reduce the frequency of endometrial mitosis. Other medications, e.g. analgesics, barbituates, can reduce the effectiveness of OCs. For adolescents, sequence preparations are preferred and should be administered only after a 1 year period of regular menstruation. Thorough check-ups should be performed on OC users twice yearly, and contraindications should be scrupulously observed.
 ...
PMID:[Effects and side effects of hormonal contraceptives]. 741 48

About one-half of patients with insulin- or non-insulin-dependent diabetes have delayed gastric emptying (diabetic gastroparesis). Some of them complain of epigastric pain, nausea, vomiting or postprandial fullness (diabetic dyspepsia), although only a minority are severely symptomatic. Diabetic gastroparesis is clinically relevant not only by virtue of the symptoms induced but also because it may contribute to inadequate glycaemic control and impaired absorption of orally administered drugs. Recent data suggest that abnormal blood glucose control, not only autonomic neuropathy, contribute to the pathogenesis of disordered gastric motility. In most cases diabetic gastroparesis is diagnosed clinically in the absence of demonstrable lesions of the upper gastrointestinal tract. To evaluate gastric emptying, scintigraphy is the 'gold standard'. Gastrokinetic drugs are of help in the treatment of gastroparesis: erythromycin is the first choice in acute presentations and cisapride for chronic symptoms. New macrolides with prokinetic action and devoid of antibacterial properties are very promising and should add another pharmacologic approach to control dyspepsia and gastroparesis in diabetic patients in the future.
 ...
PMID:Gastroparesis and dyspepsia in patients with diabetes mellitus. 749 57


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>